Syros Pharmaceuticals (SYRS) to Release Quarterly Earnings on Wednesday

Syros Pharmaceuticals (NASDAQ:SYRS) is expected to release its earnings data before the market opens on Wednesday, March 26th. Analysts expect Syros Pharmaceuticals to post earnings of ($0.70) per share for the quarter.

Syros Pharmaceuticals Stock Down 25.2 %

SYRS opened at $0.05 on Tuesday. The company has a market cap of $1.23 million, a PE ratio of -0.02 and a beta of 1.31. Syros Pharmaceuticals has a twelve month low of $0.03 and a twelve month high of $6.93. The company has a 50-day moving average price of $0.16 and a 200 day moving average price of $0.83.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Syros Pharmaceuticals in a report on Friday. They set a “sell” rating for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $3.33.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.